Ngo Huy X, Green Keith D, Gajadeera Chathurada S, Willby Melisa J, Holbrook Selina Y L, Hou Caixia, Garzan Atefeh, Mayhoub Abdelrahman S, Posey James E, Tsodikov Oleg V, Garneau-Tsodikova Sylvie
Department of Pharmaceutical Sciences , University of Kentucky , Lee T. Todd, Jr. Building, 789 South Limestone Street , Lexington , Kentucky 40536-0596 , United States.
Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention , Centers for Disease Control and Prevention , 1600 Clifton Road , Atlanta , Georgia 30329 , United States.
ACS Infect Dis. 2018 Jun 8;4(6):1030-1040. doi: 10.1021/acsinfecdis.8b00074. Epub 2018 Mar 30.
A common cause of resistance to kanamycin (KAN) in tuberculosis is overexpression of the enhanced intracellular survival (Eis) protein. Eis is an acetyltransferase that multiacetylates KAN and other aminoglycosides, rendering them unable to bind the bacterial ribosome. By high-throughput screening, a series of substituted 1,2,4-triazino[5,6 b]indole-3-thioether molecules were identified as effective Eis inhibitors. Herein, we purchased 17 and synthesized 22 new compounds, evaluated their potency, and characterized their steady-state kinetics. Four inhibitors were found not only to inhibit Eis in vitro, but also to act as adjuvants of KAN and partially restore KAN sensitivity in a Mycobacterium tuberculosis KAN-resistant strain in which Eis is upregulated. A crystal structure of Eis in complex with a potent inhibitor and CoA shows that the inhibitors bind in the aminoglycoside binding site snugly inserted into a hydrophobic cavity. These inhibitors will undergo preclinical development as novel KAN adjuvant therapies to treat KAN-resistant tuberculosis.
结核病中对卡那霉素(KAN)耐药的一个常见原因是增强型细胞内生存(Eis)蛋白的过表达。Eis是一种乙酰转移酶,可对KAN和其他氨基糖苷类进行多乙酰化,使其无法与细菌核糖体结合。通过高通量筛选,一系列取代的1,2,4-三嗪并[5,6-b]吲哚-3-硫醚分子被鉴定为有效的Eis抑制剂。在此,我们购买了17种并合成了22种新化合物,评估了它们的效力,并对其稳态动力学进行了表征。发现四种抑制剂不仅在体外抑制Eis,而且还可作为KAN的佐剂,并在Eis上调的结核分枝杆菌KAN耐药菌株中部分恢复KAN敏感性。Eis与一种强效抑制剂和辅酶A复合物的晶体结构表明,抑制剂紧密结合在氨基糖苷类结合位点,插入一个疏水腔中。这些抑制剂将作为新型KAN辅助疗法进行临床前开发,以治疗KAN耐药结核病。